Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: A LIFE substudy

Journal of Hypertension

Volumn 29, Issue 5, 2011, Pages 997-1004

  Olsen, Michael H ^a,j   Wachtell, Kristian ^b   Ibsen, Hans ^c   Lindholm, Lars ^d   Kjeldsen, Sverre E ^e   Omvik, Per ^f   Nieminen, Markku S ^g   Dahlöf, Björn ^h   Okin, Peter M ⁱ   Devereux, Richard B ⁱ  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c HOLBÆK HOSPITAL   (Denmark)

^d UMEÅ UNIVERSITY   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

albuminuria; electrocardiography; Framingham risk score; hypertension; left ventricular hypertrophy; risk factors

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; CREATININE; LOSARTAN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; ELECTROCARDIOGRAPHY; FEMALE; FRAMINGHAM RISK SCORE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORGAN INJURY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; STROKE;

EID: 79954850700     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328344daa3     Document Type: Article

References (22)

1. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-362.
2. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847. (Pubitemid 28213628)
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., ESH-ESC Task Force on the Management of Arterial Hypertension.2007. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762. (Pubitemid 47356612)
4. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
5. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27:1509-1520.
6. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302:2345-2352.
7. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356. (Pubitemid 39491919)
8. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202. (Pubitemid 40179960)
9. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343-2349. (Pubitemid 39491918)
10. Dahlö f B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998; 32:989-997.
11. Dahlö f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
12. Rowe DJ, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27 (Pt 4):297-312. (Pubitemid 20210076)
13. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306:1722-1725. (Pubitemid 23173717)
14. Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlö f B, Julius S, et al. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Press 2009; 18:348-361.
15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39:561-577. (Pubitemid 23118304)
16. Olsen MH, Sehestedt T, Lyngbæk S, Hansen TV, Rasmussen S, Wachtell K, et al. Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide: three new cardiovascular risk markers -do they improve risk prediction and influence treatment? Curr Vasc Pharmacol 2010; 8:134-139.
17. Olsen MH, Wachtell K, Okin PM, Kjeldsen SE, Dahlö f B, Devereux RB, et al. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE study. J Hum Hypertens 2002; 16:591-595. (Pubitemid 35021367)
18. Devereux RB, Dahlö f B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462. (Pubitemid 39238023)
19. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24:775-781.
20. De Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004:S2-S6.
21. Olsen MH. Assessment of cardiovascular risk: the impact and future of nontraditional cardiovascular risk markers. Eur Cardiol 2010; 6:10-13.
22. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46:33-37. (Pubitemid 40946487)